We are committed to the safety of our medicines in all cases, and maintain an active pharmacovigilance programme to help ensure this.
Our Pharmacovigilance Department manages a pharmacovigilance system for the collection, collation, and evaluation of adverse events and the implementation of effective corrective and preventive actions.
For medical information enquiries and adverse events reporting, contact: pv@hikma.com
or alternatively use our country specific contact details:
Algeria. pharmacovigilanceAlgerie@hikma.com
Canada. Canada_DrugSafety@hikma.com
Egypt. PVEgypt@hikma.com
France. francepv@hikma.com
Germany. dl-muc-qs@hikma.com
Iraq.pv@hikma.com
Italy. portugaleupharmacovigilance@hikma.com or call +351 939 610 004
Jordan. pv@hikma.com
KSA. SAPV@hikma.com
Morocco.MAPV@Hikma.com
Portugal. portugaleupharmacovigilance@hikma.com or call +351 939 610 004
The Netherlands. beneluxqapv@hikma.com
Tunisia. pv@hikma.com
US. us.hikma@primevigilance.com or call +1-877-845-0689 or 1-800-962-8364, or you can contact the FDA directly at 1-800-FDA-1088 or www.fda.gov/medwatch